恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效观察内科学(消化道病)专业论文.docxVIP

Abstract Objective: To study the efficacy and safety of entacavir in patients with decompe- nsated hepatitis B-induced cirrhosis on 24-week treatment. Method: Choose Sixty patients with HBV-Related cirrhosis were arranged to receive entecavi（r n=30）and conventional therapy（n=30）. The patients of the control group received regular support and symptomatic treatment,The patients of the entacavir group rcecived entacavir treatment(0.5 mg/d, oral) besides regular support and symptomatic treatment.The changes of serum HBV DNA, ALT, total bilirubin (TBIL), albumin (ALB) levels, of patients in two groups were investigated. Results: After 24weeks treatment, HBV DNA level ((3.1±0.9) log copies/ml) of patients in entecavir group were significantly lower than that ((6.7±0.5) log copies/ml) of patients in control group (t =19.15, P 0.05); ALB level ((37.7±7.3) g/L) of patients in entecavir group were significantly higher than that ((34.3±5.4) g/L) of patients in control group (t =2.05, P0.05); TBIL level (（15.0±4.3）μmol/L) of patients in entecavir group were significantly lower than that ( (35.3±7.4) μmol/L) of patients in control group (t =12.99, P 0.05); ALT level (（29.9±8.4）μ/L) of patients in entecavir group were significantly lower than that ( (42.8±10.2) μ/L) of patients in control group (t=5.35,P0.05).We get the quantitative comparison of the level of HBV DNA before and after treatment. The level of HBV DNA after 4,12,24week Treatment were lower than the level before treatment significantly (p 0.05). The level of ALT after 4,12, 24 weeks reatment were lower than the level of ALT before treatment significantly (p 0.05). The level of ALT after12, 24 weeks reatment were lower than the level of ALT after 4 weeks treatment significantly (p0.05). The level of TBIL after 4,12, 24 weeks treatment were lower than the level of TBIL before treatment significantly (p 0.05). The level of TBIL after12, 24 weeks treatment were lower than the level of TBIL after 4 weeks treatment sign